BVXV News and Press, BiondVax Pharmaceuticals Ltd. From 12/20/22

JERUSALEM, Dec. 20, 2022 (GLOBE NEWSWIRE) -- via InvestorWire – BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV )(“Company”), a biotechnology company, which focuses on developing, manufacturing, and commercializing innovative immunotherapeutic products primarily for the treat...

JERUSALEM, Dec. 16, 2022 (GLOBE NEWSWIRE) -- via InvestorWire – BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV) (“Company”), which focuses on developing, manufacturing, and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoim...

An analysis conducted on a 2021 poll has released results indicating that most patients suffering from plaque psoriasis have reported symptoms in intertriginous areas, which sometimes prevents them from seeking medical guidance. The researchers looked into the sexual, psychosocial and mental im...

BiondVax (NASDAQ: BVXV) , a biotechnology company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, today announced the receipt of formal notifications from the Nasdaq Stock Market that...

BiondVax Pharmaceuticals ( NASDAQ: BVXV ) has regained compliance with Nasdaq regarding minimum stockholders’ equity and minimum bid price. The company previously reported on Sept. 30, 2022, and Nov. 2, 2022, receipt of the respective non-compliance notifications. For...

JERUSALEM, Dec. 12, 2022 (GLOBE NEWSWIRE) -- via InvestorWire – BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV) (“BiondVax”), a biotechnology company focused on developing, manufacturing, and commercializing innovative products for the prevention and treatment of infectious ...

As mobile phones, social media and apps have taken center stage in our lives, several experts have become increasingly worried about the amount of time the average person spends looking at screens. On average, people around the world spend nearly seven hours daily on their screens, with the ave...

BiondVax Pharmaceuticals (NASDAQ: BVXV) , a biotech company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, has appointed a new scientific advisory board member: Dr. Matthias Dobbelst...

LOS ANGELES, Dec. 06, 2022 (GLOBE NEWSWIRE) -- via InvestorWire – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) , a biopharmaceutical company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and ...

Jerusalem, Dec. 06, 2022 (GLOBE NEWSWIRE) -- via InvestorWire – BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a biotechnology company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune ...